Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 8 Neoplasms by Site 4 Digestive System Neoplasms 4 Pancreatic Neoplasms 3 Neoplasms, Glandular and Epithelial 3 Digestive System Diseases 3 Colorectal Neoplasms 3 Pancreatic Diseases 2 Neoplasms by Histologic Type 2 Endocrine Gland Neoplasms 2 Carcinoma, Pancreatic Ductal 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Adenocarcinoma 2 Thymus Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Respiratory Tract Neoplasms 1 Rectal Diseases 1 Previously Treated Metastatic Colorectal Cancer 1 Pancreatic cancer, adult 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Intestinal Neoplasms 1 Intestinal Diseases 1

Interventions

Capecitabine 77 pembrolizumab 70 Oxaliplatin 68 Cisplatin 56 Fluorouracil 52 Paclitaxel 41 Trastuzumab 37 Nivolumab 35 Leucovorin 27 Docetaxel 27 Irinotecan 22 Ramucirumab 20 Gemcitabine 15 Bevacizumab 15 S 1 (combination) 14 Carboplatin 13 atezolizumab 12 apatinib 12 fludarabine 11 Cyclophosphamide 11 tislelizumab 10 Drug Therapy 10 Injections 8 130-nm albumin-bound paclitaxel 8 trastuzumab deruxtecan 7 durvalumab 7 Ipilimumab 7 Folfox protocol 7 Albumin-Bound Paclitaxel 7 titanium silicide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Stomach Neoplasms × napabucasin × Clear all

NCT02178956 2023-11-15

BRIGHTER

Sumitomo Pharma America, Inc.

Phase 3 Completed

714 enrolled 16 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡